Home / News

News

RYBREVANT® plus LAZCLUZE™ shows statistically significant and clinically meaningful improvement in overall survival versus osimertinib 

J&J는 EGFRxMET 이중항체 ‘아미반타맙 (제품명 리브리반트)’와 유한양행이 개발해 J&J에 라이선스아웃한 3세대 EGFR TKI ‘레이저티닙 (제품명 라즈클루즈)’가 타크리소 대비 환자의 OS를 통계적으로, 임상적으로 유의미하게 개선했다고 밝힘. 

Read More »
January 10, 2025 No Comments

European Commission approves RYBREVANT® in combination with LAZCLUZE® for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer 

유럽연합 집행위원회는 EGFR 변이 진행성 비소세포폐암 환자의 1차 치료제로 J&J의 RYBREVANT®(amivantamab)와 유한양행이 개발해 J&J에 라이선스아웃한LAZCLUZE®(lazertinib)와의 병용 요법을 승인함. The European Commission has approved the combination

Read More »
January 10, 2025 No Comments

RYBREVANT® plus LAZCLUZE™ by Johnson & Johnson got approved by the U.S. FDA as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer. LAZCLUZE™ is anti-cancer drug developed by Yuhan Corporation licensed out to Janssen Biotech in 2018.  

Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) for the first-line treatment of adult patients

Read More »
August 20, 2024 No Comments